187 related articles for article (PubMed ID: 35508455)
1. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer.
Lee TY; Hsu CH; Fan HL; Liao GS; Chen TW; Chan DC
Eur J Surg Oncol; 2022 Sep; 48(9):1972-1979. PubMed ID: 35508455
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Analysis of Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: a Propensity Score-Matched Analysis.
Liu L; Zheng L; Liu S; Zhang M; Zhang S; Jiang Z; Qin C; Wang D
J Gastrointest Surg; 2023 Nov; 27(11):2297-2307. PubMed ID: 37715013
[TBL] [Abstract][Full Text] [Related]
3. A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer.
Liu L; Sun L; Zhang N; Liao CG; Su H; Min J; Song Y; Yang X; Huang X; Chen D; Chen Y; Zhang HW; Zhang H
Int J Hyperthermia; 2022; 39(1):239-245. PubMed ID: 35100917
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience.
Allievi N; Bianco F; Pisano M; Montori G; Fugazzola P; Coccolini F; Lotti M; Mosconi S; Merelli B; Campanati L; Lucianetti A; Ansaloni L; Magnone S
Updates Surg; 2023 Jan; 75(1):159-167. PubMed ID: 36371549
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis? - A propensity score matching study.
Zheng Y; Zhang J; Chen C; Gong Z; Wang Z; Deng Q; Yu S; Hu Y; Liu Y; Cao H; Xiao Q; Wang J; Ding K; Sun L
Eur J Surg Oncol; 2024 Feb; 50(2):107958. PubMed ID: 38219698
[TBL] [Abstract][Full Text] [Related]
6. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S
Langenbecks Arch Surg; 2021 Sep; 406(6):1847-1857. PubMed ID: 33704561
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study.
Yu P; Huang X; Huang L; Dai G; Xu Q; Fang J; Ye Z; Chai T; Du Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11491-11498. PubMed ID: 37392201
[TBL] [Abstract][Full Text] [Related]
8. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S
Langenbecks Arch Surg; 2021 Jun; 406(4):1071-1080. PubMed ID: 33611693
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
10. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study.
Beeharry MK; Zhu ZL; Liu WT; Yao XX; Yan M; Zhu ZG
BMC Cancer; 2019 Sep; 19(1):932. PubMed ID: 31533660
[TBL] [Abstract][Full Text] [Related]
11. [The safety and efficacy of prophylactic hyperthermic intraperitoneal chemotherapy for elderly patients with locally advanced gastric cancer: a propensity score matching analysis].
Yu T; Ma FH; An Q; Cao XL; Xiao G; Wu GJ
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(36):2867-2873. PubMed ID: 37726993
[No Abstract] [Full Text] [Related]
12. Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.
Graziosi L; Cantarella F; Mingrone E; Gunnellini M; Cavazzoni E; Liberati M; Donini A
Ann Ital Chir; 2013; 84(5):551-6. PubMed ID: 24140896
[TBL] [Abstract][Full Text] [Related]
13. Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial.
Koemans WJ; van der Kaaij RT; Wassenaar ECE; Boerma D; Boot H; Sikorska K; Los M; Grootscholten C; Hartemink KJ; Veenhof AAFA; Kodach L; Snaebjornsson P; van Sandick JW
J Surg Oncol; 2021 Mar; 123(4):904-910. PubMed ID: 33428786
[TBL] [Abstract][Full Text] [Related]
14. [Effects of laparoscopic hyperthermic intraperitoneal perfusion chemotherapy combined with intraperitoneal and systemic chemotherapy treatment in patients with untreated gastric cancer with peritoneal metastasis].
Li S; Xue K; Dai HM; Wang YK; Shan F; Li ZY; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):442-447. PubMed ID: 37217352
[No Abstract] [Full Text] [Related]
15. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients.
Costa WL; Coimbra FJ; Ribeiro HS; Diniz AL; de Godoy AL; Begnami M; Silva MJ; Fanelli MF; Mello CA
World J Surg Oncol; 2012 Sep; 10():195. PubMed ID: 22992263
[TBL] [Abstract][Full Text] [Related]
16. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
17. Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis.
Patel M; Arora A; Mukherjee D; Mukherjee S
Int J Surg; 2023 Aug; 109(8):2435-2450. PubMed ID: 37158149
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology.
Badgwell B; Ikoma N; Murphy MB; Wang X; Estrella J; Roy-Chowdhuri S; Das P; Minsky BD; Lano E; Song S; Mansfield P; Ajani J
Ann Surg Oncol; 2021 Jan; 28(1):258-264. PubMed ID: 32556731
[TBL] [Abstract][Full Text] [Related]
19. Morbidity following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases with or without early postoperative intraperitoneal chemotherapy: A propensity score matched study.
Dranichnikov P; Graf W; Cashin PH
Eur J Surg Oncol; 2022 Jul; 48(7):1598-1605. PubMed ID: 35177313
[TBL] [Abstract][Full Text] [Related]
20. Comparative Study of the Efficacy and Safety of Radical Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Gastric Cancer: A Propensity Score-Matching Analysis.
Shen C; Lin Y; Guo X; Li Y; Wang D; Du Z; Hu P; Chen X; Zeng X; Lv J; Wu C; Tao K
Ann Surg Oncol; 2022 Dec; 29(13):8551-8563. PubMed ID: 35941344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
